Market Insights
Nonalcoholic steatohepatitis (NASH) is also known as “fatty liver,” a disorder that develops in patients who are not alcoholics and mainly causes liver damage that is diagnostically indistinguishable from alcoholic hepatitis. The key risk factors observed in patients suffering from NASH are obesity, glucose intolerance, and dyslipidemia. The challenges that are faced in the diagnosis of the disease are mainly due to a poor understanding of pathogenesis linked to insulin resistance, especially in obesity or metabolic syndrome. Market experts suggest that most of the patients are asymptomatic, and laboratory findings related to NASH mainly include elevations in aminotransferase levels.
However, in the diagnosis of NASH, biopsy plays a key role in diagnosis. According to the American Liver Foundation, NASH is the third leading cause of liver transplant in the U.S.; a database suggests more than 12% of the general population has NASH, and approximately 2.7% have advanced liver fibrosis due to the disease. NASH comprises the treatment of obesity, insulin-sensitizing agents, lipid-lowering agents, antioxidants, and hepatoprotective therapy. In NASH treatment, weight reduction has been widely studied in adults and has shown improvement in not only the biochemical results but also the histology.
According to the Cleveland Clinic, the reduction of dietary carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve the lipid profile in overweight patients. Several drugs have been studied, including sibutramine, a serotonin reuptake inhibitor, and orlistat, which reduce fat absorption. Both of these have been shown to improve liver enzyme levels and sonographic signs of a fatty liver. A meta-analysis of rimonabant, a cannabinoid-1-antagonist, showed that it is associated with increased adverse events, and currently, it cannot be recommended for NAFLD.
In the case of insulin-sensitizing agents, peroxisome proliferator-activated receptor gamma (PPARg) agonists (pioglitazone’s) have projected improvement in insulin resistance by acting as surrogate markers of fatty liver and promoting redistribution of triglycerides from the liver and muscle into proliferating adipocytes. According to a recently published review article that was conducted by an expert panel from the “Chilean Gastroenterological Society” and the “Chilean Hepatology Association,” pioglitazone, along with vitamin E, is a proven pharmacological choice for patients with biopsy-proven NASH, but evidence on its long-term safety and efficacy is lacking. Moreover, the guidelines of the American Association for the Study of Liver Diseases indicate pioglitazone as a possible therapeutic drug for the treatment of NASH.
North America was observed as the largest market for NASH treatment, followed by Europe. In North America, the rising prevalence of obesity and the increasing incidence of diabetes is the key factors assisting the NASH treatment market. According to the Cleveland Clinic, the prevalence of overweight persons in the US has risen to more than 65%, and obesity is now present in more than 30% of the adult US population.
The prevalence is increased in men, older individuals (those aged 40–70 years), and those with components of metabolic syndrome, especially diabetes and abdominal obesity. The prevalence of childhood obesity and nonalcoholic fatty liver disease (NAFLD) is at similar levels. NAFLD has been observed in all ethnic groups, with the highest prevalence seen in Hispanics compared with Caucasians and African Americans. Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period of 2016–2022.
The global nonalcoholic steatohepatitis (NASH) treatment market is segmented on the following bases:
Type of Treatment
- Tabular Representation of Phase II and I Drugs
- Projected sales of Phase III drugs are estimated to continue until 2023 (US$ Mn).
- Pipeline Analysis (Phase I, Phase II, and Phase III Clinical Trials)
- Polyunsaturated fatty acids
- Monounsaturated fatty acids
- Angiotensin-receptor blockers
- Angiotensin-converting enzyme inhibitors
- Other Agents
- Pentoxifylline
- Betaine
- N-acetylcysteine
- Vitamine E
- Antioxidants
- Gemfibrozil
- Lipid-Lowering Drugs
- Pioglitazone
- Rosiglitazone
- Thiazolidinedione
- Metformin
- Insulin-Sensitizing Agents
- Orlistat
- Sibutramine
- Weight Loss Treatment
Geography
- North America
- Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Key players identified for the nonalcoholic steatohepatitis (NASH) treatment market include but are not limited to:
The key players in the market are AstraZeneca Plc, Galmed Pharmaceuticals Ltd., GENFIT SA, Gilead Sciences, Novo Nordisk, Immuron Ltd., Intercepts Pharmaceuticals, Enzo Biochem, Inc., Conatus Pharmaceuticals, Raptor Pharmaceutical Corp., Tobira Therapeutics, Inc., and others.
This report offers the following:
- An overview of the global markets for nonalcoholic steatohepatitis (NASH) treatment
- Market trends assessment for the period 2013-2023, with historical information for 2013, 2014, and 2015, and projections through 2023, with respective CAGRs during 2016-2023
- Qualitative assessment tools such as market drivers, challenges, and opportunities
- Market competition scrutiny tools such as market share analysis, fractal map assessment, and Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
- A general overview of the industry structure
- Company profiles highlight key information about the major players operating in the nonalcoholic steatohepatitis (NASH) treatment market
